Clinical trials: Durability
Type 2 Diabetes Mellitus
VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
The purpose of this study was to determine whether the initiation of a vildagliptin plus metformin combination regimen would result in more durable glycemic control than metformin monotherapy in treatment-naïve patients with…
- Trial name
- NCT01528254
- Testing
- vildagliptin, Metformin
- Where
- 227 sites in Argentina, Australia and 32 more
- Volunteers
- 2,004 people
- Sponsor
- Novartis Pharmaceuticals
Edematous Fibrosclerotic Panniculopathy
Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
This is a Phase 2b, rollover, long-term study to evaluate the safety and duration of efficacy of EN3835 in the treatment of women with EFP.
- Trial name
- NCT03893890
- Testing
- Previously Treated with EN3835
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Hepatitis B
Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial
The purpose of this study is to evaluate the durability of antiviral activity in chronic hepatitis B patients who showed complete response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 trial.
- Trial name
- NCT00362674
- Where
- 27 sites in South Korea
- Sponsor
- Bukwang Pharmaceutical
Aortic Valve Disease
Trifecta™ Durability Study
The Trifecta™ Durability Study was a multi-center, prospective, single-arm, post-market study conducted in Europe and Canada to collect long-term safety and performance data on the Trifecta™ valve.
- Trial name
- NCT01256710
- Testing
- Trifecta™ aortic bioprosthesis
- Where
- Germany
- Volunteers
- 1,151 people
- Sponsor
- Abbott Medical Devices
Corneal Ectasia
Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery
The objectives of this post market registry are to evaluate the safety and durability of treatment effect up to 3 years following cross-linking performed with Photrexa Viscous (riboflavin 5'- phosphate in 20% dextran ophthalmic…
- Trial name
- CXL (NCT03319082)
- Testing
- Corneal Collagen Cross-linking
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Glaukos Corporation
Hepatitis C
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study.
- Trial name
- NCT01721265
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis
A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)
This study is for people with cystic fibrosis who took part in a previous study with a medicine called BI 3720931. The main purpose of this study is to monitor the long-term health of participants who were treated with BI 3720931…
- Trial name
- NCT06962852
- Testing
- BI 3720931
- Where
- 5 sites in France, Italy and 3 more
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
HIV-1-infection
ART First-line Treatment Durability in Russia
This study is a non-interventional retrospective study. Data from patients who signed informed consent form will be collected through retrospective chart or medical records review.
- Trial name
- NCT04253119
- Testing
- Antiretroviral/Anti HIV
- Where
- 4 sites in Russia
- Volunteers
- 536 people
- Sponsor
- MSD Pharmaceuticals LLC
Schizophrenia
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
- Trial name
- NCT01626456
- Testing
- ALKS 9072, Low, ALKS 9072, High
- Where
- 82 sites in United States, Bulgaria and 6 more
- Volunteers
- 478 people
- Sponsor
- Alkermes, Inc.
Rheumatoid Arthritis
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require…
- Trial name
- NCT03109470
- Sponsor
- Pope Research Corporation
Adhesive Capsulitis, Frozen Shoulder
Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)
This is a long-term follow-up study to evaluate the safety and durability (efficacy) of response to EN3835 compared to placebo in participants who were treated in EN3835-210 or the pivotal Phase 3 parent studies for the treatment…
- Trial name
- NCT04680156
- Where
- 30 sites in United States
- Volunteers
- 120 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cardiovascular Disease
Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease
This study is being conducted to evaluate the safety and the length of effect on platelet build-up in the arteries of Durlaza™ as compared to immediate-release Bayer® aspirin 81 mg or subject's current aspirin 81 mg of choice in…
- Trial name
- DURATION (NCT02370680)
- Testing
- Aspirin, Durlaza™
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- New Haven Pharmaceuticals, Inc.
Metabolic Acidosis
Long-term Safety Extension to Study TRCA-301
This study is a 40-week, blinded, placebo-controlled extension of Study TRCA-301 (NCT03317444). Eligible subjects who complete the 12-week treatment period in Study TRCA-301 have the option to participate in this extension study…
- Trial name
- NCT03390842
- Testing
- TRC101
- Where
- 29 sites in United States, Bulgaria and 5 more
- Volunteers
- 196 people
- Sponsor
- Tricida, Inc.
Diabetes Mellitus, Type 2
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
This study will compare insulin lispro low mixture [LM] and insulin glargine both in combination with the patient's oral diabetes medicines, for their ability to control blood sugar in patients with type 2 diabetes and compare…
- Trial name
- IOOV (NCT00279201)
- Testing
- Insulin glargine, Lispro Low Mix, Lispro Mid Mix
- Where
- 199 sites in United States, Argentina and 10 more
- Volunteers
- 2,091 people
- Sponsor
- Eli Lilly and Company
Cellulite, Laxity; Skin
Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity
All participants who completed the EN3835-224 study will be invited to participate in this observational study to evaluate long term durability of response and safety.
- Conditions
- Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy
- Trial name
- NCT05249257
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Systemic Lupus Erythematosus
GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Open label safety and efficacy follow-up.
- Trial name
- NCT00082511
- Testing
- Prasterone (GL701)
- Where
- 22 sites in United States, Mexico
- Volunteers
- 114 people
- Sponsor
- Genelabs Technologies